| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 112.670 +12.01% on 12/12/25 | | 128.600 -1.87% on 12/23/25 | +3.000 (+2.44%) since 11/24/25 |
| 3-Month | 112.670 +12.01% on 12/12/25 | | 142.800 -11.62% on 10/03/25 | -0.600 (-0.47%) since 09/24/25 |
| 52-Week | 100.400 +25.70% on 04/09/25 | | 160.000 -21.13% on 12/27/24 | -28.600 (-18.48%) since 12/24/24 |
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value,...
Feedback from U.S. Food and Drug Administration (FDA) supports advancement into a pivotal Phase 3 trial and a 505(b)(2) regulatory pathway Phase 3 SURPASS-IPF trial remains...
LYT-200 demonstrated favorable tolerability and strong efficacy in a heavily pretreated population, both in combination with standard of care and as a monotherapy, supporting advancement toward a potentially...
LYT-200 continues to demonstrate strong evidence of clinical activity, survival benefit and a highly favorable safety profile in heavily pretreated relapsed/refractory AML patients, both as a monotherapy...
Data presented at the CHEST 2025 Annual Meeting highlight deupirfenidone’s differentiated profile and potential to address unmet needs across age groups
Patients who switched from placebo or pirfenidone to deupirfenidone in the open-label extension study achieved stabilization of lung function with favorable tolerability ...
GlyphAgo is an oral prodrug of agomelatine, a medicine with established clinical efficacy in generalized anxiety disorder (GAD) GlyphAgo is designed to overcome a key...
Achieved meaningful progress toward key value inflection points across our diversified portfolio, with multiple programs advancing into or toward late-stage development ...
Deupirfenidone to be advanced by PureTech’s newly launched Founded Entity, Celea Therapeutics
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2025, on Thursday, August 28, 2025. ...
| 3rd Resistance Point | 130.000 |
| 2nd Resistance Point | 129.000 |
| 1st Resistance Point | 127.600 |
| Last Price | 126.200 |
| 1st Support Level | 125.200 |
| 2nd Support Level | 124.200 |
| 3rd Support Level | 122.800 |
| 52-Week High | 160.000 |
| Fibonacci 61.8% | 137.233 |
| Fibonacci 50% | 130.200 |
| Last Price | 126.200 |
| Fibonacci 38.2% | 123.167 |
| 52-Week Low | 100.400 |